Drug Profile

Research programme: cancer therapeutics - Phio Pharmaceuticals

Alternative Names: sd-rxRNA based therapeutics

Latest Information Update: 28 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator RXi Pharmaceuticals
Developer Phio Pharmaceuticals
Class Antineoplastics; Small interfering RNA
Mechanism of Action Gene silencing; Programmed cell death 1 receptor antagonists; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2024 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals
02 Aug 2018 RXi Pharmaceuticals has patent protection for sd-rxRNA platform in European Union and Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com